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ABSTRACT 
 
Aim: To evaluate the early response to treatment to an antiangiogenetic drug (sorafenib) in a 
heterotopic murine model of hepatocellular carcinoma (HCC) using ultrasonographic molecular 
imaging. 
Material and Methods: the xenographt model was established injecting a suspension of HuH7 
cells subcutaneously in 19 nude mice. When tumors reached a mean diameter of 5-10 mm, they 
were divided in two groups (treatment and vehicle). The treatment group received sorafenib (62 
mg/kg)  by  daily  oral  gavage  for  14  days.  Molecular  imaging  was  performed  using  contrast 
enhanced ultrasound (CEUS), by injecting into the mouse venous circulation a suspension of 
VEGFR-2 targeted microbubbles (BR55, kind gift of Bracco Research, Geneve, Switzerland). 
Video clips were acquired for 6 minutes, then microbubbles (MBs) were destroyed by a high 
mechanical index (MI) impulse, and another minute was recorded to evaluate residual circulating 
MBs. The US protocol was repeated at day 0,+2,+4,+7, and +14 from the beginning of treatment 
administration. Video clips were analyzed using a dedicated software (Sonotumor, Bracco Swiss) 
to  quantify  the  signal  of  the  contrast  agent.  Time/intensity  curves  were  obtained  and  the 
difference  of  the  mean  MBs  signal  before  and  after  high  MI  impulse  (Differential  Targeted 
Enhancement-dTE)  was  calculated.  dTE  represents  a  numeric  value  in  arbitrary  units 
proportional to the amount of bound MBs. At day +14 mice were euthanized and the tumors 
analyzed for VEGFR-2, pERK, and CD31 tissue levels using western blot analysis. 
Results: dTE values decreased from day 0 to day +14 both in treatment and vehicle groups, and 
they were statistically higher in vehicle group than in treatment group at day +2, at day +7, and at 
day +14. With respect to the degree of tumor volume increase, measured as growth percentage 
delta (GPD), treatment group was divided in two sub-groups, non-responders (GPD>350%), and   3
responders (GPD<200%).  In the same way  vehicle  group was divided in slow  growth  group 
(GPD<400%), and fast growth group (GPD>900%). dTE values at day 0 (immediately before 
treatment  start)  were  higher  in  non-responders  than  in  responders  group,  with  statistical 
difference at day 2. While dTE values were higher in the fast growth group than in the slow 
growth group only at day 0. A significant positive correlation was found between VEGFR-2 
tissue  levels  and  dTE  values,  confirming  that  level of  BR55  tissue enhancement  reflects  the 
amount of tissue VEGF receptor.   
Conclusions: the present findings show that, at least in murine experimental models, CEUS with 
BR55 is feasable and appears to be a useful tool in the prediction of tumor growth and response 
to sorafenib treatment in xenograft HCC.  
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INTRODUCTION  
 
Hepatocellular carcinoma (HCC) is the third leading cause of cancer death world-wide 
and ranks as the fifth most common cancer diagnosis globally. Unlike most malignancies, some 
risk  factors,  such  as  cirrhosis,  viral  hepatitis  (e.g.  hepatitis  B  and  hepatitis  C),  alcohol  liver 
disease, aflatoxin exposure, metabolic liver disease from nonalcoholic steatohepatitis (NASH), 
and hemochromatosis significantly increase the probability to develop HCC.
1 For these reasons, 
the management of HCC is strictly conditioned by the degree of liver disease and eventually by 
the  stage  of  organic  failure  (“Child-Pugh  score”).
2,3  Recently  a  wide  consensus  in  the 
management of HCC patients was found with the Barcelona Clinic Liver Cancer (BCLC) Staging 
System.  Following  these  guidelines,  patients  with  early  HCC  are  candidates  for  curative 
treatments, such as surgical resection, transplantation, or local ablation via percutaneous ethanol 
injection  or  radiofrequency.  Patients  with  intermediate  HCC  benefit  from  arterial 
chemoembolization, whereas patients with advanced HCC might receive antioangiogenetc drugs 
(Sorafenib).
4  
In a phase III randomized placebo-controlled trial, sorafenib was found to improve survival in 
patients  with  advanced-stage  HCC.
5,6  Sorafenib  is  a  tyrosine  kinase  inhibitor  of  several 
intracellular  proteins  suspected  to  be  important  in  tumor  progression,  including  the  platelet 
derived  growth factor  receptor-b  (PDGFRb),  raf  kinase,  and  the vascular endothelial  growth 
factor receptors (VEGFR), VEGFR-1, VEGFR-2, and VEGFR-3.
1 In preclinical studies sorafenib 
was found to block the RAF/MEK/ERK pathway, to inhibit tumor angiogenesis and to induce 
tumor cell apoptosis in HCC models.
7  
However  the  effects  of  tumor  stasis  and  shrinkage,  obtained  by  the  administration  of  an 
antiangiogenetic drug, are usually only transitory, and, after a fleeting period of clinical benefit,   5
the tumor starts to growth again. In other cases no appreciable clinical effect can be obtained with 
the therapy, because of a totally refractoriness of the tumor. Multiple mechanisms are suspected 
to  underlie  the  modes  of  resistance  to  antiangiogenetic  treatments,  through  the  evasions  to 
therapies or because a substantial indifference to the drug.
8,9 For these reasons it is important to 
monitor the efficacy of the antiangiogenetic therapy in order to differentiate between responders 
and non-responders patients, and to suspend the drug administration in those subjects who do not 
have benefits and might develop drug toxicity.
6  
The criteria of response to treatment used for tumor treated with conventional chemotherapy 
(RECIST  criteria)  are  based  on  the  volume  reduction  of  the  neoplasia  during  the  drug 
administration.
10 However antiangiogenetic molecules might not induce tumor shrinkage even in 
presence of intra-tumoral vascular reduction and necrosis, and traditional criteria in evaluation of 
response  to  treatment  might  underestimate  drug  efficacy  when  these  molecules  are  used. 
Considering this, a modified version of RECIST criteria, created in 2008, evaluates the response 
to  treatment  measuring  the  reduction  in  viable  tumor  area,  assessed  using  contrast-enhanced 
radiological techniques.
11    
The  development  of  antiangiogenetic  drugs  that  interfere  with  specific  pathways  of  vascular 
proliferation raised the need to find more sensitive imaging techniques in order to better access 
drug  efficacy  and  response  to  therapy  in  cancer  patients.  Molecular  imaging  refers  to  the 
characterization  and  measurement  of  biological  processes  at  the  molecular  level,  including 
techniques  such  as  positron  emission  tomography,  molecular  magnetic  resonance  imaging, 
magnetic  resonance  spectroscopy,  optical  bioluminescence,  optical  fluorescence,  and  targeted 
ultrasound. However the cost and the utilization of ionizing radiations limit the use in patients of 
the majority of the above mentioned techniques. In contrast, ultrasound (US) is the most widely   6
used imaging technique, is inexpensive, portable, and provides noninvasive real-time imaging.
12-
14   
Ultrasound contrast agents are small, 1 to 4 micron in diameter, microbubbles (MBs) made of a 
gaseous core surrounded by a lipid or albumin shell. They behave hemodynamically like red 
blood  cells,  and  for  this  reason  they  have  the  unique  property  to  work  as  true  intravascular 
tracers.
14,15 VEGF is one of the most potent growth factors of the vascular endothelial cells. The 
circulating  VEGF  acts  on  some  endothelium-specific  tyrosine  kinase  receptors  (VEGFR-1, 
VEGFR-2, VEGFR-3), that are over-expressed in tumor endothelial cells and promote vascular 
proliferation.
16,17 Some VEGFR-2 targeted ultrasound contrast agents have been developed and 
used in experimental studies in order to monitor tumor angiogenesis and treatment efficacy.
14,18    
BR55  (Bracco  Research  SA,  Geneva,  Switzerland)  is  a  novel  VEGFR-2  specific  targeted 
microbubble contrast agent for the molecular imaging of angiogenesis. In contrast with other 
VEGFR-2  targeted  MBs,  BR55  does  not  require  an  antibody  for  binding  nor  uses 
biotin/streptavidin coupling strategy, but it contains a lipopeptide inserted in the phospholipid 
shell of the MB membrane. This lipopeptide is composed of a heteridimer peptide selected for its 
high  affinity  for  human  VEGFR-2,  but  that  is  seen  to  selective  react  also  with  rat  vascular 
receptor. Because of the absence of streptavidin, highly immunogenic in human patients, BR55 is 
designed in view of future clinical applications.
19-21 
The purpose of our study is to investigate the usefulness of BR55 US contrast agent as an early 
predictor of  response  to  treatment  with  an  antiangiogenetic drug  (sorafenib) in  a  heterotopic 
murine model of HCC.  
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MATERIAL AND METHODS  
 
Experimental model 
Human  cell line Huh7,  kindly provided by Dr.  Porretti, was maintained and expanded using 
standard  cell  culture  technique  in  high  glucose  Dulbecco’s  Modified  Eagle  Medium
b 
supplemented with L-glutamine, 1% ampicillin/amphotericin B and 10% foetal bovine serum. 
The  model  was  established  by  subcutaneous  injection  of  5x10
6  cells  suspended  in  sterile 
phosphate-buffered saline
c for a total volume of 0.2 mL per injection into the right flank of 6-8 
weeks old female nude mice
d. During the experiments, the mice were maintained with regular 
mouse chow and water ad libitum in a temperature-controlled room under a 12-hour light/dark 
cicle and specific pathogen-free circumstances. Mice were randomized to vehicle or treatment 
with sorafenib
a (BAY 43-9006) at a dosage of 62 mg/Kg by daily oral gavage. Sorafenib was 
formulated as previously described.
22 Growth of established xenografts was monitored at least 
twice weekly by US. The treatment started when tumours reached 5-10 mm in diameter and 
lasted for 14 days. The protocol was approved by the Ethical Committee of the University of 
Bologna. 
 
Targeted contrast enhanced ultrasound imaging 
Imaging examinations were performed using an ultrasound unit
e equipped with a linear array 4-
13 MHz probe. Mice were anesthetized intraperitoneally with 0.2 mL of a solution constituted by 
one part of ketamine
 f 10%, one part of xylazine
g 20 mg/mL, and eight parts of sterile water. The 
anesthetized animals were placed on a heating support in order to keep constant the temperature 
for  all  the  duration  of  the  experiment.  All  the  tumors  were  first  visualized  with  Bmode 
ultrasonography in two perpendicular scan plains in order to measure the maximal diameters of   8
the mass and to calculate its volume, through the formula: height x width x thickness/2. For 
contrast enhanced ultrasonography (CEUS), ultrasound coupling gel was applied on the skin and 
the  probe  was  placed  on  a  fixed  mechanical  support in  order to  maintain  the  same scanned 
section of the tumor for all the duration of the US. A contrast specific software (Contrast Tune 
Imaging, CnTI) was activated in a dual display modality (Bmode window and contrast window). 
The following US setting were used and maintained unvaried for all the experiment: dynamic 
range,  7  dB;  acoustic  power,  30  kPa;  mechanical  index,  0.03;  depth,  22-37  mm;  time-gain 
compensation, linear. 
VEGFR-2 targeted MBs contrast agent
h was reconstituted injecting 2 ml of a sterile 5% glucose 
solution  through  the  septum  of  the  vial.    After  dissolution  of  the  cake,  the  resulting  MB 
suspension was collected through a needle inserted through the rubber stopper. A volume of 50 ml 
of MB suspension (2.4x10
7 MBs) was injected into the mouse venous circulation through the 
retro-orbital sinus. Immediately after the injection a video clip was acquired continuously for 6 
minutes  at  low  MI,  then  the  MBs  present  into  the  tumor  were  destroyed  by  increasing  the 
acoustic power (MI 1.9). Video acquisition continued for 1 minute after MBs destruction in order 
to evaluate residual circulating MBs during the replenishment of the tumor. 
The same procedure protocol was repeated at different time points starting from the beginning of 
the treatment (0, +2, +4, +7 and +14 days). 
 
Post-processing analysis of ultrasound data 
Post processing analysis of US video clips, recorded as DICOM files, was performed using a 
dedicated software
i. This software is designed to quantify contrast echo-power within a region of 
interested (ROI) comprehending all the tumor area. The analysis applies first linearization at the 
pixel  levels  to  revert  the  effects  of  “log”  compression  in  the  ultrasound  system.  Contrast   9
enhancement  in  the  ROI  was  expressed  as  relative  echo-power  values  (rms2),  which  are 
proportional to the number of MBs in the selected ROI.
21 The software automatically recognizes 
the high MI flash frames, and it considers for quantifications only the 2 seconds before the flash 
and the 10 seconds following the 15
th second after the flash. The signal intensity (defined as 
targeted  enhancement,  TE),  before  and  after  destruction  (respectively  TEbd  and  TEad)  were 
subtracted in order to obtain the differential targeted enhancement (dTE=TEbd-TEad). Since the 
TEbd is proportional to both the circulating and the bind MBs, whereas TEad corresponds only to 
circulating MBs that are reperfusing the tumor after high MI destruction, the difference between 
them (dTE) represents a numeric value proportional to the amount of bound MBs to the target 
receptor VEGFR-2.  
 
Necroscopy 
At day +14, after the last measurement and still under anaesthesia, animals were euthanized by 
intraperitoneally  injection  of  0.1  mL  of  a  solution  of  embutramide,  mebezonium  iodide  and 
tetracaine hydrochloride
j. Tumor were dissected and stored in 4% paraformaldehyde. A slice of 
all tumours were also frozen in liquid nitrogen vapour and stored at –80°C. 
 
Western blot analysis    
Three monoclonal antibodies (Ab) against VEGFR2
k (diluted at 1:1000), phospho-p44/42 MAPK 
(Erk1/2; Thr202/Tyr204)
l (diluted  at 1:1000) and CD31
m (diluted  at 1:1000), were incubated 
separately for 16 hours at 4°C. A horseradish conjugated secondary Ab
n (diluted at 1:7500) was 
incubated for 45 minutes at room temperature and the corresponding band was revealed using the 
enhanced chemoluminescence method
o. Digital images of autoradiographies were acquired with a 
quantitative imaging system
p and band signals were acquired in the linear range of the scanner   10
using  a  specific  densitometric  software
q.  Images  were  calibrated  against  a  reference 
autoradiography  and  given  in  relative  density  units.  After  autoradiography  acquisition,  the 
membranes  were stripped  and  reprobed  for  two hours  at  room temperature with anti b-actin 
antibody
r (diluted at 1:500) to normalize protein loading. A ratio between VEGFR2/phospho-
ERK/CD31 and b-actin corresponding bands was used to quantify the levels of each protein 
(normalized value). This ratio was divided by b-actin levels of HuH7 line in each blot in order to 
compare the results in different running gels (absolute value).   
 
Statistical analysis 
Data  are  presented  as  median  values.  Differences  in  dTE  between  treated  and  untreated, 
responder and non-responder, and fast growth and slow growth tumours were compared using the 
Mann-Whitney test (2-tailed). Percentage delta of variation of tumour volume was calculated 
using the formula [(final value-starting value)/starting value]%. Data of dTE and VEGFR-2 were 
compared using a Spearman’s rank test. A p<0.05 was considered significant. Statistical analysis 
was performed using a dedicated software
s.   
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RESULTS 
 
Tumor model and targeted ultrasound findings 
A number of 19 mice (10 in the treatment group and 9 in the vehicle group) were studied from 
the beginning to the end of the protocol.  Median tumor volume was 608.02 mm
3 (333.3-1799.88) 
at day 14 in the treatment group and 893.43 mm
3 (218.67-1996.70) in the vehicle group (Fig. 1), 
with  a  growth  percentage  delta  of  192.76%  (84.72-739.48)  in  treatment  group  and  747.56% 
(73.47-2887.62) in vehicle group.  
 
 
Figure 1. Median tumor volumes in treatment and vehicle group at different times from the beginning of drug 
administration. Median tumor volume for treatment group is 184.89 mm
3 at day 0 and 608 mm
3 at day 14 (growth 
percentage delta: 192.76%); while in vehicle group mean tumor volume is 124.61 mm
3 at day 0 and 893.43 mm
3 at 
day +14 (growth percentage delta: 747.56 %). 
 
Median values of dTE  in treated and vehicle groups at different days are listed in table 1. The 
lowest value for treatment group was observed at day +7, while the lowest value for vehicle   12
group was recorded at day +4 (Fig 2). At day +2, +7 and +14 dTE values in treatment group were 
consistently lower than in vehicle group (p=0.002, p=0.001 and p=0.009 respectively).  
 
dTE  Treatment group  Vehicle Group  p value 
Day 0  1,82E+07  2,94E+07  NS 
Day +2  1,24E+07  2,55E+07  0.022 
Day +4  3,44E+02  6,87E+06  NS 
Day +7  1,21E+06  8,69E+06  0.001 
Day +14  2,53E+06  1,05E+07  0.009 
 
Table 1. dTE values (expressed as arbitrary units) for treatment and vehicle groups at different days from starting 
treatment-placebo administration. A significant difference between dTE in the two groups was seen at day +2, day 
+7, and day +14, with higher dTE values in vehicle group with respect to treatment group. A p<0.05 was considered 
significant. 
 
 
 
Figure 2. Median contrast enhanced derived dTE values for treatment and vehicle group at different times from the 
beginning of drug administration. dTE is calculated by subtracting the signal intensity from the microbubbles before 
and after a high mechanical index impulse. Significantly higher dTE values are reported in treatment group at day +2 
(p=0.022), at day +7 (p=0.001), and at day +14 (p=0.009). 
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Treatment group was divided in two sub-groups with respect to growth percentage delta (GPD). 
Tumors with a GPD<200% were considered as responders to treatment (6 cases, ranging from 
85% to 199%). Tumors with a GPD>350% were defined as non-responders (4 cases, ranging 
from 382% to 739%). Median tumor volume for responders group was 272,92 mm
3 at day 0 and 
523.56 mm
3 at day +14. Median tumor volume for non-responders group was 107,07 mm
3 at day 
0 and 761.69 mm
3 at day +14.  
As for treatment group, vehicle group was divided in two subgroups with respect to their GPD. 
Tumors with slow growth had a GPD<400% (4 mice), whilst tumor with fast growth presented a 
value >900% (5 mice). Median tumor volume for slow growth group was 159,22 mm
3 at day 0 
and 602,71 mm
3 at day +14. Median tumor volume for fast growth group was 105,41 mm
3 at day 
0 and 1940,80 mm
3 at day +14. Figure 3 shows mean volumes for the four groups at different 
days.  
 
 
Figure 3. Median tumor volumes in the four treatment and vehicle sub-groups at different times from the beginning 
of drug administration. With respected to the growth percentage delta (GPD, calculated by the formula [(final value-
starting  value)/starting  value]%),  treatment  group  is  divided  in  responders  (GPD<200%)  and  non-responders 
(GPD>350%);  while  vehicle  group  is  divided  in  slow  growth  group  (GPD<400%),  and  fast  growth  group 
(GPD>900%).  
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Higher values in dTE are reported for non-responders to treatment and fast growth untreated 
groups at day 0, while from day +4 both treatment groups present lower dTE value than the two 
vehicle groups (Fig. 4 and Table 2).  
 
dTE 
Non-
responders 
Responders  Slow growth  Fast growth 
Day 0  5.92E+07  1.41E+07  1.69E+07  3.85E+07 
Day 2  2.56E+07  9.22E+06  2.80E+07  2.49E+07 
Day 4  5.39E+06  2.72E+06  7.72E+06  6.87E+06 
Day 7  1.62E+06  9.98E+05  1.14E+07  7.79E+06 
Day 14  4.39E+06  1.89E+06  1.50E+07  5.54E+06 
 
Table 2. Median dTE values for treatment groups (non-responders and responders), and vehicle groups (slow and 
fast growth) at different times from the beginning of drug administration.  
 
A significance difference in dTE values exists between responders and non-responders at day +2 
(p=0.019).  
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Figure 4. A. Mean dTE values and confidence intervals for treatment groups. A progressive reduction in dTE values 
is present for non-responders (green bars) and responders (blue bars) between day 0 and day +7, with a slight 
increase between day +7 and day +14. Higher values of dTE were measured for non-responders with respect to 
responders at all days from the beginning of drug administration. Statistical difference was present between non-
responders and responders (blue bars) only at day +2 (p=0.019). B. Mean dTE values and confidence intervals for 
vehicle groups. Higher values of dTE were measured at day 0 in fast growth groups (green bars), while from day +2 
to day +14 dTE values became higher in slow growth group (blue bars).    
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Figure 5. Contrast enhanced ultrasound images of two tumors after injection of a VEGFR-2 targeted ultrasound 
contrast agent (BR55). The images refer to sixth minute after injection, before the high mechanical index (MI) 
destruction impulse. Bound microbubbles (MBs) are represented as stationary bright colored speckles within the 
tumor.  For  quantification  analysis  a  region  of  interest  is  drawn  in  order  to  comprehend  all  the  tumor  area. 
Subsequently the software automatically quantifies some frames before and after the high MI flash and it creates a 
time-intensity diagram with signal intensity (expressed as echo-power, measured in arbitraty units) plot in the y axis, 
and time (as seconds) in the x axis. The difference between the echo-power before and after MBs destruction (dTE) 
is proportional to the amount of MBs bound to the VEGFR-2 receptor. In the upper panel a tumor from the vehicle 
group is shown. A certain amount of bound MBs is visible at day 0 (left), day +2 (middle), and day +14 (right). An 
example of a treated tumor is shown in the lower panel. Compared with the vehicle tumor no appreciable signal is 
evident from bound MBs at day +2 and at day +14.     17
Western blot analysis  
Western blot analysis for VEGFR-2, CD31 and pERK were performed for 16 tumor slices, at day 
+14. For technical reasons three tumors were excluded from western blot evaluation (1 from 
vehicle group, and 2 from treatment group). The data presented as median values and standard 
deviations are listed in table 3. No statistical difference was found between VEGFR-2, CD31, and 
pERK at day  +14  between  the four  sub-groups  (non  responders  and  responders  to  treatment 
tumors, and slow and fast growth vehicle groups).     
  Non-respoders  Responders  Slow growth  Fast growth 
VEGFR-2/b-actin  4,269 (26,063-0,616)  1,043 (1,463-0,134)  0,945 (1,046-0,562)  1,781 (2,245-0,886) 
VEGFR-2/ HuH7 b-actin   0,200 (01,218-0,029)  0,049 (0,068-0,006)  0,051 (00,056-0,030)  0,096 (0,121-0,048) 
CD31/b-actin  0,883 (12,523-0,354)  0,605 (2,172-0,124)  1,028 (1,525-0,172)  1,210 (2,856-0,144) 
CD31/HuH7 b-actin   0,041 (0,585-0,016)  0,028 (0,102-0,006)  0,055 (0,082-0,009)  0,065 (0,153-0,008) 
pERK/b-actin  5,346 (10,646-0,570)  0,893 (1,216-0,467)  1,007 (1,401-0,612)  0,752 (2,153-0,362) 
pERK/HuH7 b-actin   0,250 (0,585-0,017)  0,044 (2,172-0,124)  0,054 (0,082-0,009)  0,040 (0,116-0,019) 
 
Table 3 Results from quantification of western blot analysis. Median and min and max (round brackets) values are 
expressed as arbitrary units derived from comparison between VEGFR-2, CD31, pERK levels and b-actin levels for 
each tumor (normalized values); absolute values were calculated considering the ratio between normalized values 
and HuH7 b-actin levels in order to compare data from different running blots. No statistical difference was found 
between western blot values in the four groups (responders and non-responders to treatment, and slow and fast 
growth  from  vehicle  receiving  mice).  However,  even  in  absence  of  statistical  significance,  higher  values  of 
normalized  and  absolute  VEGFR-2  level  were  seen  in  non-responders  and  fast  growth  tumors,  compared  with 
responders and slow growth ones. Normalized and absolute values of CD31 were higher in vehicle groups and in 
non-responders group. pERK normalized and absolute levels were higher in non-responders and slow growth groups 
and slightly lower in responders and fast growth tumors.  
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Considering all tumors in all groups, VEGFR-2 levels expressed as absolute values ([VEGFR-
2/b-actin]/HuH7  b-actin)  were  significantly  related  to  dTE  values  at  day  +14  (R=0.635  and 
p=0.008).     19
DISCUSSION 
 
In our study we observed that ultrasound molecular imaging using a VEGFR-2 targeted 
microbubble contrast agent (BR55) can be a useful tool to monitor the response to treatment to an 
antiangiogenetic drug in a xenograft model of HCC. Signal intensity from bound MBs, measured 
as dTE, was statistically lower in treatment group with respect to vehicle group, very early after 
the beginning of drug administration (day +2), and the difference remained significant during the 
following  days  (+7,  and  +14).  When  treatment  group  was  divided  in  responder  and  non-
responders, considering the degree of volume increase, dTE were higher in non-responders sub-
group  at each day when compared to responders, and this was still evident at day 0, before 
treatment  was  started.  However,  because  of  the  wide  overlap  between  values,  statistical 
difference was present only at day +2.   
Sorafenib is a multiple kinase inhibitor that specifically acts on VEGFR-1, VEGFR-2, VEGFR-3, 
PDGFRb, and raf kinase and it is proved to prolong survival time in patients with advanced 
HCC. However the response rate to sorafenib is actually quite low (2-3%).
1,23 The mechanism of 
development  of  resistance  to  antiangiogenetic  drugs  is  still  not  well  clarified.  Drug  induced 
hypoxia may lead to induction of hypoxia-regulated factors and other pro-angiogenetic factors 
that finally produce a rebound effect of tumor angiogenesis, with recruitment of new endothelial 
cells,  and  vascular  remodeling  and  stability.  It  is  known  that  different  tumors  may  express 
different kinds of angiogenic factors, and therefore endothelial cells may exhibit a tissue type-
dependent response to therapies.
9,24 In xenograft models, in which tumor is generated by direct 
injection of a cell line, the endothelial cells invading the tumor derive from the mice. For this 
reason, the difference in response to treatment observed in our experiment, should be, at least in 
part,  host-dependent.  Monitoring  anti-tumoral  therapy  is  essential  in  order  to  identify  the   20
occurrence of drug resistance. Dimensional criteria for evaluation of tumor response to treatment 
might be not suitable to monitor response to antiangiogenetic therapy, because of lack of volume 
shrinkage even in presence of intra-tumoral vascular reduction and necrosis. Molecular imaging 
targeted for specific vascular pathways might be more sensitive in predicting treatment efficacy.
25 
The expression of VEGF protein is found to correlate with clinicopathological factors such as 
proliferation, vascular invasion, and tumor multiplicity in HCC. Moreover VEGF expression is 
reported to associate not only with invasion and metastasis of HCC, but also with postoperative 
recurrence.
16 No data are available regarding VEGFR-2 levels and tumor aggressiveness in HCC 
patients.  However,  considering  the  mitogenic  effect  of  circulating  VEGF  ligand  on  vascular 
proliferation  and  VEGFR-2  overexpression  in  tumoral  endothelial  cells,  targeting  molecular 
imaging  for  this  specific vascular  receptors  might  be  useful in  recognizing  more  aggressive, 
vascularized tumors, potentially less respondent to antiangiogenetic treatment.  
We observed that non-responders tumors as well as fast growth ones, showed higher VEGFR-2 
targeted MBs signal, measured as dTE value, before starting treatment. It can be speculated that 
tumors with high VEGFR-2 values present a more aggressive behavior, faster growth, and a less 
response to sorafenib.  
BR55 is designed to bind to VEGFR-2 vascular receptor, with high affinity and specificity.
19,21 In 
our  experiment  we  observed  that  the  amount  of  bound  BR55  MBs  is  statistically  related  to 
tumoral  VEGFR-2  expression,  measured  through  western  blot  analysis,  at  day  +14.  We 
hypothesize that this correlation was present also before starting treatment at day 0, and during 
the follow-up period. However, further investigations are needed to confirm this observation.   
A progressive reduction in dTE values was observed also in non-treated tumors between day 0 
and day +4, with a slight increase between day +4 and day +14. This might be explained because 
of the extension of large necrotic areas secondary to rapid tumor volume increase in absence of   21
adequate  vascular  proliferation. Considering  that  the production  of VEGF  is  dependent  upon 
tumor  cell  mass,
26  the  reduction  of  the  effective  vital  tumoral  area  might  be  responsible  of 
transient reduce of vascular proliferation and VEGFR-2 expression, with decreased BR55 uptake.  
Another possible explanation for dTE reduction in vehicle group might be attributable to a partial 
persistence of ligation of the lipopeptide construct of BR55 to the VEGFR-2 into the tumor. We 
hypothesize that after injection the bounding sub-unit of BR55 remained attached to the vascular 
receptor for more than a few minutes, even for some days, interfering with specific bind of new 
MBs, and subsequently reducing contrast uptake and finally dTE values. When the US schedule 
became less frequent, the lipopeptide had enough time to completely release from VEGFR-2, and 
dTE values started to increase, as seen between day +4 and +7, and more clearly between day +7 
and  +14.  In  vitro  studies  showed  that  BR55  MBs  are  displaced  from  VEGFR-2  by  specific 
monoclonal  Ab  miming  VEGF  ligand.  However  only  partial  displacement  occurs  if  low 
concentrations  of  Ab  were  used.
19  Considering  our  in  vivo  experiment,  if  circulating  VEGF 
concentrations  weren’t  high  enough  to  induce  complete  detachment  of  BR55,  the  remaining 
bound MB subunits might act as competitors for the new  contrast agent.  Further studies  are 
needed to confirm or confute this hypothesis, in order to evaluate possible residual persistence of 
BR55 subunits into the tumor, even many hours after contrast agent injection.   
Western blot analysis for CD31 was used to quantify vascular density in tumor slices. Lower 
values  of  CD31  were  obtained  for  treatment  group  with  respect  to  vehicle  group.  Moreover 
responders subgroup showed lower CD31 concentrations that responders tumors, and similarly 
slow growth subgroup had lower CD31 values than fast growth one. These data indicate that 
sorafenib inhibited vascular proliferation in treated compared to non-treated tumors, and that the 
inhibition was more efficacious in responders than non-responders and in slow growth than fast 
growth sub-groups.     22
We also analyzed pERK concentration in tumor slices through western blot. Phosphorylated ERK 
is  the  key  downstream  target  of  the  RAF/MEK/ERK  cascade  that  represents  a  fundamental 
signaling pathway involved in the regulation of normal mammalian cell proliferation, survival 
and differentiation. A dysregulation of this pathway is implicated in the molecular pathogenesis 
of HCC.
27-29 In experimental studies sorafenib is seen to block the RAF/MEK/ERK pathway in a 
dose dependent fashion.
7 In our study we observed that pERK expression was higher in non-
responders tumors compared to responders, and to vehicle tumors. These results highlight the fact 
that some tumors, even if treated with sorafenib, might be refractory to drug effect, and even 
over-express pERK with respect to untreated HCCs. In an in vitro study Zhang and colleagues 
observed that baseline pre-treatment pERK was differently expressed in different HCC cell lines 
and that it seemed to be correlated with their metastatic potential and response to sorafenib. Cell 
lines with lower basal levels of pERK were significantly less sensitive to sorafenib-mediated 
growth inhibition that the other cell lines with higher pERK levels.
28 However in another in vitro 
study sorafenib was seen to inhibit ERK-1/2 phosphorylation at pharmacological concentrations 
in human bladder cancer cells, while at low concentrations sorafenib significantly stimulated 
ERK-1/2  phosphorylation.  With  respect  to  these  data  the  authors  concluded  that  sorafenib 
exhibits a dual (activatory and inhibitory) mode of action in a panel of human bladder cell lines.
29 
In our experiment we used the full dose of sorafenib reported in the literature  for xenograft 
models.
22  This  dose  represents  the  therapeutic  murine  dose  calculated  from  human 
pharmaceutical dose and we considered it high enough to produce therapeutic effect without 
major toxicity in the mouse.  
We didn’t measured pERK concentrations in tumors at baseline, before starting treatment, so we 
are not able to evaluate the trend of increase in ERK phosphorylation in the tumor model we 
used.  However,  the  higher  values  in  pERK  observed  in  non-responders  tumors  might  be   23
interpreted as a sorafenib induced stimulatory effect on pERK. Another possible explanation of 
this behavior can be found in the wide variability of response to treatment of different HCCs, 
with an escape to sorafenib mediated inhibitory effect and activation of other signaling pathways 
that  act  on  ERK phosphorylation.  Further  studies are  needed  to  elucidate  this  results  and  to 
evaluate the changes in pERK in different HCCs treated with sorafenib.      
 
Conclusions  
Contrast enhanced ultrasonography is a promising technique to monitor the efficacy on anti-
angiogenetic drugs  for  the  treatment of  hypervascularized  tumors.  In  clinical oncology some 
studies  reported  the  usefulness  of  non-targeted  MBs  for  the  early  diagnosis  of  response  to 
treatment.
30-34 However molecular US might be a more specific and sensitive tool in evaluating 
tumor functional changes. In our study we observed that CEUS using a VEGFR-2 targeted MB 
contrast agent (BR55) can early predict the response to treatment with sorafenib in a xenograft 
model of HCC, allowing to distinguish between responders and non-responders tumors, even 
before starting treatment. The bounding subunit of BR55 is represented by a lipoptide construct 
that is directly incorporated in the phospholipid-based microbubble shell, without the use of Ab. 
For  these  reasons,  BR55  doesn’t  own  immunogenic  properties,  and  might  be  safely  used  in 
human beings. According to these observations CEUS using BR55 contrast agent might be a 
future useful technique for monitoring anti-tumoral therapies in clinical oncology.      
 
Footnotes 
a  Nexavar, Bayer S.p.A., Milan, Italy 
b Gibco® DMEM, Invitrogen S.r.L., San Giuliano Milanese (MI), Italy.   24
c Gibco® Phosphate-buffered saline (10X), liquid, Invitrogen S.r.L., San Giuliano Milanese (MI), 
Italy. 
d CD1 nude, Charles River, Sant’Angelo Lodignano (LO), Italy. 
e MyLab70 XVG, Esaote, Florence, Italy. 
f Ketavet 100, Intervet Productions S.r.l., Aprilia (LT), Italy 
g Rompun®, Bayer HealthCare, Milan, Italy 
h BR55, Bracco Swiss SA, Geneva, Switzerland 
i Sonotumor (version 4.0.4), Bracco Research SA, Geneva, Switzerland 
j Tanax, Intervet/Schering Plough Animal Health S.r.l., Milan, Italy 
k 55B11, Cell Signaling Technology, Inc. Danversa, MA, USA 
l 20G11, Cell Signaling Technology, Inc. Danversa, MA, USA 
m ab28364, Abcam, Cambridge, MA, USA  
n labeled polymer-HRP antimouse, Envision system DAKO Cytomation, Carpinteria, CA, USA 
o Amersham Biosciences, GE Healthcare Europe GmbH, Glattbrugg, Switzerland 
p Fluor-S MultiImager, Bio-Rad, Hercules, CA, USA 
q Quantity-one, Bio-Rad, Hercules, CA, USA 
r beta-Actin (C4), Santa Cruz Biotechnology, Inc. Santa Cruz, CA, USA 
s SPSS 16.0, SPSS Inc., Chicago, USA   25
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